Skip to content
2000
Volume 10, Issue 4
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

A series of 3-styrylbenzimidamides were synthesized and biologically evaluated in a cell free FRET assay as potential BACE1 inhibitors. Some of the synthesized analogues were discovered to have moderate BACE1 inhibitory activities with IC50 values ranging from 9.3 to 295.8 μM. Molecular docking study proposed that the most potent compound (E)-2d bound to BACE1 differently in S3-S2' subpockets forming no polar interaction with the catalytic Asp dyad compared with the 3-styrylbenzimidamides. The results would contribute to the further optimizations on benzimidamide scaffold to achieve novel small molecular BACE1 inhibitors with improved potencies.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/1570180811310040003
2013-05-01
2025-09-18
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/1570180811310040003
Loading

  • Article Type:
    Research Article
Keyword(s): 3-styrylbenzimidamide; Alzheimer's disease; BACE1 inhibitors; CADD
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test